AbolerIS Pharma
/ 1 Rue Gaston Veil
44000 Nantes
FR
AbolerIS Pharma
Foundation date
28/11/2019
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.
IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.
Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.
Upcoming events
All events-
1212 '22
Type 2 Immunity in Homeostasis and Disease (2nd edition)
Event by: VIB -
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation
Latest news
More news-
Company growth prompts Connected-Pathology relocation to larger laboratory facilities to accommodate increase in study capacity
23 hours ago
Read more
-
Japan welcomes companies, startups and knowledge institutions from Flanders
Friday December 2nd 2022
Read more
-
FIT stimulates market diversification with renewed subsidy
Thursday December 1st 2022
Read more
Jobs
More jobs-
07/12/22
Brussels
Postdoctoral position in cancer immunology and the tumor immune microenvironment
Permanent
VIB -
-